UY38010A - Anticuerpos de alfa-sinucleína y sus usos - Google Patents
Anticuerpos de alfa-sinucleína y sus usosInfo
- Publication number
- UY38010A UY38010A UY0001038010A UY38010A UY38010A UY 38010 A UY38010 A UY 38010A UY 0001038010 A UY0001038010 A UY 0001038010A UY 38010 A UY38010 A UY 38010A UY 38010 A UY38010 A UY 38010A
- Authority
- UY
- Uruguay
- Prior art keywords
- antibodies
- alpha
- synuclein
- sinucleine
- alfa
- Prior art date
Links
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 4
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 4
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000032859 Synucleinopathies Diseases 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a anticuerpos que se unen a alfa–sinucleína y a sus fragmentos capaces de unirse a alfa–sinucleína como monómero y en fibrillas y a la prevención de la agregación de alfa–sinucleína inducida por fibrillas de alfa–sinucleína. Los anticuerpos de la presente invención son para usar en el tratamiento de alfa–sinucleinopatías, incluida la enfermedad de Parkinson.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1720975.0A GB201720975D0 (en) | 2017-12-15 | 2017-12-15 | Anti-alpha synuclein antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38010A true UY38010A (es) | 2019-07-31 |
Family
ID=61009086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038010A UY38010A (es) | 2017-12-15 | 2018-12-14 | Anticuerpos de alfa-sinucleína y sus usos |
Country Status (24)
Country | Link |
---|---|
US (2) | US11261242B2 (es) |
EP (1) | EP3724224A1 (es) |
JP (2) | JP7292279B2 (es) |
KR (1) | KR20200099160A (es) |
AR (1) | AR115192A1 (es) |
AU (1) | AU2018382530A1 (es) |
BR (1) | BR112020010504A2 (es) |
CA (1) | CA3083199A1 (es) |
CL (1) | CL2020001605A1 (es) |
EA (1) | EA202091478A1 (es) |
EC (1) | ECSP20039623A (es) |
GB (1) | GB201720975D0 (es) |
IL (1) | IL275187A (es) |
MA (1) | MA51135A (es) |
MX (1) | MX2020005691A (es) |
PE (1) | PE20201061A1 (es) |
PH (1) | PH12020551007A1 (es) |
SG (1) | SG11202004502SA (es) |
TN (2) | TN2020000069A1 (es) |
TW (2) | TW202332692A (es) |
UA (1) | UA126295C2 (es) |
UY (1) | UY38010A (es) |
WO (1) | WO2019115674A1 (es) |
ZA (2) | ZA202003542B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3051839A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
EA202190807A1 (ru) * | 2018-10-19 | 2021-08-06 | Янссен Вэксинс Энд Превеншн Б.В. | Антитела к синуклеину |
WO2021055881A1 (en) * | 2019-09-20 | 2021-03-25 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
US20230025256A1 (en) * | 2019-12-04 | 2023-01-26 | Simon Friedman | Protein blocking assembly and methods of making and using |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
WO2002050121A1 (fr) | 2000-12-13 | 2002-06-27 | Taisho Pharmaceutical Co.,Ltd. | Nouvel anticorps |
CA2466841A1 (en) | 2001-11-21 | 2003-06-05 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
SI2361928T1 (sl) | 2003-05-19 | 2017-07-31 | Prothena Biosciences Limited | Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
EA013752B1 (ru) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
WO2007021255A1 (en) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
EP2118300B1 (en) | 2007-02-23 | 2015-05-27 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
ES2546863T3 (es) | 2007-02-23 | 2015-09-29 | Prothena Biosciences Limited | Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica |
JP5747414B2 (ja) | 2008-04-29 | 2015-07-15 | バイオアークティック ニューロサイエンス アーベー | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン |
CA2746778C (en) | 2008-12-19 | 2019-04-23 | University Of Zurich | Human anti-alpha-synuclein autoantibodies |
US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
EP2539366B1 (en) | 2010-02-26 | 2017-11-08 | BioArtic Neuroscience AB | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
US20160077112A1 (en) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of Misfolded Proteins |
US9910049B2 (en) | 2014-09-11 | 2018-03-06 | Amprion, Inc. | Detection of misfolded amyloid beta protein |
US10989718B2 (en) | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
JP5980790B2 (ja) | 2010-11-05 | 2016-08-31 | ブランダイス ユニバーシティBrandeis University | バイオマーカーとしての、ice切断されたアルファ−シヌクレイン |
DE102011008153B4 (de) | 2011-01-08 | 2018-08-09 | Aj Roboscreen Gmbh | Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein |
CA2839563C (en) | 2011-06-23 | 2019-10-29 | Biogen Idec International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
KR101600733B1 (ko) * | 2011-10-28 | 2016-03-09 | 프로테나 바이오사이언시즈 리미티드 | 알파-시누클레인을 인식하는 인간화된 항체 |
DK2807188T3 (da) | 2012-01-27 | 2019-10-07 | Prothena Biosciences Ltd | Humaniserede antistoffer, der genkender alpha-synuclein |
ES2856272T3 (es) | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígenos para eliminar antígenos agregados |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
EP3071974A2 (en) | 2013-11-19 | 2016-09-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
RU2697098C1 (ru) | 2013-11-21 | 2019-08-12 | Ф.Хоффманн-Ля Рош Аг | Антитела к альфа-синуклеину и способы применения |
CA2944402A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
US10155030B2 (en) | 2014-05-23 | 2018-12-18 | University Of South Florida | Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック, インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
WO2017033152A1 (en) | 2015-08-25 | 2017-03-02 | Prothena Biosciences Limited | Methods for detecting phosphorylated alpha-synuclein |
JP6976249B2 (ja) | 2015-11-23 | 2021-12-08 | サンガモ セラピューティクス, インコーポレイテッド | 免疫を工学操作するための方法および組成物 |
EP3440225A4 (en) | 2016-04-06 | 2020-03-11 | Imago Pharmaceuticals, Inc. | THERAPEUTIC ANTIBODIES FOR TREATING NEURODEGENERATION |
UA124733C2 (uk) | 2016-06-02 | 2021-11-10 | Медімм'Юн Лімітед | Антитіло до альфа-синуклеїну |
GB201611840D0 (en) | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
WO2018039147A1 (en) | 2016-08-23 | 2018-03-01 | The Johns Hopkins University | THERAPEUTIC USES OF LAG3 THE α-SYNUCLEIN TRANSMISSION RECEPTOR |
WO2018091444A1 (en) | 2016-11-15 | 2018-05-24 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
US20180134777A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (11D12) |
US20180134775A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (7A11) |
US20180134776A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (4H6) |
EP3551228A4 (en) | 2016-12-12 | 2020-08-12 | The Michael J. Fox Foundation For Parkinson's Research | ANTIBODIES FOR HUMAN ALPHA SYNUCLEIN |
BR112018016717A2 (pt) | 2016-12-16 | 2018-12-26 | H Lundbeck As | agentes, usos e métodos |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
EP3567054A4 (en) | 2017-01-06 | 2021-03-10 | ABL Bio Inc. | ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF |
EP3565636B1 (en) | 2017-01-09 | 2024-01-03 | California Institute of Technology | Use of gut microbiota in the diagnosis of parkinson's disease |
CA3051839A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
JOP20190227A1 (ar) | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | تركيبات وطرق لعلاج اعتلالات السينوكلين |
EP3635393A4 (en) | 2017-05-16 | 2021-03-10 | Claudio Soto-Jara | DETECTION OF MISFOLDED TAU PROTEIN |
WO2018237338A1 (en) | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | ANTI-ALPHA-SYNCUCIN ANTIBODIES AND METHODS OF USE |
-
2017
- 2017-12-15 GB GBGB1720975.0A patent/GB201720975D0/en not_active Ceased
-
2018
- 2018-12-13 CA CA3083199A patent/CA3083199A1/en active Pending
- 2018-12-13 MA MA051135A patent/MA51135A/fr unknown
- 2018-12-13 EP EP18829767.5A patent/EP3724224A1/en active Pending
- 2018-12-13 PE PE2020000707A patent/PE20201061A1/es unknown
- 2018-12-13 TN TNP/2020/000069A patent/TN2020000069A1/en unknown
- 2018-12-13 UA UAA202002941A patent/UA126295C2/uk unknown
- 2018-12-13 TN TNP/2021/000169A patent/TN2021000169A1/en unknown
- 2018-12-13 EA EA202091478A patent/EA202091478A1/ru unknown
- 2018-12-13 MX MX2020005691A patent/MX2020005691A/es unknown
- 2018-12-13 AU AU2018382530A patent/AU2018382530A1/en active Pending
- 2018-12-13 JP JP2020532596A patent/JP7292279B2/ja active Active
- 2018-12-13 WO PCT/EP2018/084697 patent/WO2019115674A1/en active Application Filing
- 2018-12-13 US US16/771,993 patent/US11261242B2/en active Active
- 2018-12-13 KR KR1020207019487A patent/KR20200099160A/ko not_active Application Discontinuation
- 2018-12-13 SG SG11202004502SA patent/SG11202004502SA/en unknown
- 2018-12-13 BR BR112020010504-0A patent/BR112020010504A2/pt unknown
- 2018-12-14 TW TW112114559A patent/TW202332692A/zh unknown
- 2018-12-14 AR ARP180103657A patent/AR115192A1/es unknown
- 2018-12-14 UY UY0001038010A patent/UY38010A/es not_active Application Discontinuation
- 2018-12-14 TW TW107145283A patent/TWI801469B/zh active
-
2020
- 2020-06-07 IL IL275187A patent/IL275187A/en unknown
- 2020-06-12 ZA ZA2020/03542A patent/ZA202003542B/en unknown
- 2020-06-14 PH PH12020551007A patent/PH12020551007A1/en unknown
- 2020-06-15 CL CL2020001605A patent/CL2020001605A1/es unknown
- 2020-07-14 EC ECSENADI202039623A patent/ECSP20039623A/es unknown
-
2021
- 2021-05-21 ZA ZA2021/03456A patent/ZA202103456B/en unknown
-
2022
- 2022-01-26 US US17/585,174 patent/US20220220192A1/en active Pending
-
2023
- 2023-06-05 JP JP2023092397A patent/JP2023127585A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38012A (es) | Anticuerpos de alfa-sinucleína y sus usos | |
CR20230477A (es) | MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593) | |
UY38010A (es) | Anticuerpos de alfa-sinucleína y sus usos | |
CO2017003048A2 (es) | Moléculas de unión a antígeno biespecíficas activadoras de células t que se unen a cd3 y al receptor 1 de folato (folr1) | |
CL2020001637A1 (es) | Anticuerpos para lilrb2 | |
CO2017005240A2 (es) | Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción | |
GT201700033A (es) | Anticuerpos anti tigit | |
ECSP19020740A (es) | Anticuerpos anti-cd27 | |
ECSP19029758A (es) | Anticuerpos anti-il-33 y usos de los mismos | |
PE20171556A1 (es) | Agentes de union a cd123 y usos de estos | |
UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
AR102658A1 (es) | Composición para el tratamiento de telas | |
NI201800134A (es) | Anticuerpos antifactor de la coagulación xi | |
BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
PE20170258A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
CL2020001629A1 (es) | Anticuerpos de unión a hla-a2/wt1. | |
CU20170012A7 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
MX2020009130A (es) | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. | |
CL2019002735A1 (es) | Anticuerpos que se unen a steap-1. | |
AR114808A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA | |
DOP2019000082A (es) | Anticuerpos anti-il-33 y usos de los mismos | |
AR119639A1 (es) | Moléculas de anticuerpo para cd73 y sus usos | |
AR120118A2 (es) | Anticuerpos anti tigit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20231114 |